NCT02984566Active, not recruiting
Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)
LARK: Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)
Source: ClinicalTrials.gov · Last updated 19 May 2026
Brief summary (registry, in English)
Primary and secondary liver cancer patients will receive liver SABR with or without KIM intervention.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 32 (actual)
- First submitted
- 23 Nov 2016
- Start date
- 14 Jan 2020
- Primary completion date
- Jul 2026
- Lead sponsor
- University of Sydney
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT02984566
What you commit to
- Study type: Interventional
- Participants enrolled: 32
- From 14 Jan 2020 to the primary completion date, Jul 2026
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous radiation to the liver (including SIRTEX)
- On systemic antineoplastic drug therapy within 7 days before inclusion
Other illness
- HCC/cholangiocarcinoma with evidence of metastatic disease including nodal or distant metastases
- Metastatic disease with complete liver disease response to first-line chemotherapy (i.e. no target for SBRT)
- Untreated HIV or active hepatitis B/C
Other
- Pregnant or lactating women
Who the study is looking for
- ECOG performance status 0-1
- Life expectancy \>6 months
- Number of lesions: ≤ 3
- Lesion size : \< 10 cm for a single lesion (and up to 10 cm cumulative diameter for multiple lesions)
- Child-Pugh A or B7 within 6 weeks prior to study entry
- Unsuitable for RFA or resection or transplant
- Distance from GTV to luminal structures (i.e., oesophagus, stomach, duodenum, small or large bowel) ≥ 10mm
- All blood work obtained within 6 weeks prior to study entry with adequate organ function
- May have had previous surgery, RFA or ethanol injection
- Patient must have been discussed at multidisciplinary tumour board with consensus opinion for SBRT
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peter MacCallum Cancer Centre Coordinator of this site? Confirm its status | Melbourne | Australia | Unknown status |
| Nepean Hospital Coordinator of this site? Confirm its status | Penrith | Australia | Unknown status |
| Westmead Hospital Coordinator of this site? Confirm its status | Westmead | Australia | Unknown status |
| Princess Alexandra Hospital Coordinator of this site? Confirm its status | Woolloongabba | Australia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.